Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jun 26, 2013 10:32pm

17 Views

Post# 21575278

RE:Fierce biotech RE Esperiop and biotech ipo's in favor!

Clearly, there are some more pessimistic views of ETC-1002 (see link below). Personally, I think ETC-1002 sounds promising, but an IPO of $14/share may be a bit steep. I kind of agree with the author of this article, that the IPO price of ESPR is a bit high, but I do see a lot of potential for this drug. So keep ESPR on your radar, but in my opinion don't buy in yet until you see how the market changes the share price. Perhaps RVX-208 should start a trial in combination with ETC-1002? :)

https://seekingalpha.com/article/1522512-esperion-therapeutics-another-ipo-after-pfizer-abandons-the-only-drug-in-its-pipeline?source=yahoo

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024